ArticleFrontiers in pediatrics2026
National respiratory syncytial virus acute respiratory infection burden of disease estimate in Mexican children under 2 years.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: National population-based respiratory syncytial virus (RSV) direct burden-of-disease estimates on outpatient, emergency room (ER) and hospitalization settings are scarce among Mexican children. These estimates are key to inform the development of preventive public policies and to strengthen seasonal clinical planning in Mexico. Methods: A systematic review of literature allowed estimating robust RSV-proportions in acute respiratory infection (ARI) and lower respiratory tract infection (LRTI) studies in Mexican children 0 to 23 months-old (<2yo) and length-of-stay, mortality rates, mechanical ventilation use, and seasonality patterns for RSV-attributed cases that could be scaled nationally. These results allowed the estimation of outpatient and ER visits, hospitalizations, total length-of-stay and deaths of RSV-related illnesses from national databases available in the public domain for the 2011-2023 period. Incidence rates were also calculated considering the official population projections for the period analyzed. Results: RSV-proportions accounted for 31.76% and 16.03% of outpatient visits in children 0 to 11 months-old (<1yo) and children 12 to 23 months-old (1yo) respectively; In <2yo RSV-proportions were 17.96% in ER and 20.25% (pneumonia) to 34.72% (bronchiolitis) in hospitalization. Mean length-of-stay and mortality were highest in preterm <1yo (7.04 days, 2.11%) followed by at-term <1yo (5.77 days; 1.4%) and 1yo (4.77; 0.87%). Mechanical ventilation followed a similar trend (12.24%, 5.77% and 2.03%). Seasonally (96% autumn-winter), RSV caused in <2yo ∼772,450 outpatient visits, ∼185,326 ER visits, and ∼26,873 hospitalizations. Annual rates per 1,000 children were ∼248 and ∼107 in <1yo and 1yo respectively in outpatient settings; ∼55, ∼30 in ER settings and ∼32 in preterm <1yo, ∼9 at-term <1yo and ∼4 in 1yo in hospitalization settings. Conclusions: RSV burden-of-disease was seasonal, imposing a major burden on healthcare facilities during autumn-winter. Children <1yo were the most affected in the three clinical settings analyzed. These results can be used to calculate the financial RSV burden-of-disease as well as to inform the development of preventive policies and to strengthen seasonal clinical planning in Mexico.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.